Novo Nordisk A/S (NVO)
| Market Cap | 216.87B |
| Revenue (ttm) | 49.11B |
| Net Income (ttm) | 17.49B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.93 |
| PE Ratio | 12.59 |
| Forward PE | 13.23 |
| Dividend | $1.23 (2.49%) |
| Ex-Dividend Date | Aug 18, 2025 |
| Volume | 19,991,318 |
| Open | 48.78 |
| Previous Close | 50.04 |
| Day's Range | 48.49 - 49.47 |
| 52-Week Range | 45.05 - 113.02 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 80.40 (+62.56%) |
| Earnings Date | Nov 5, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $80.4, which is an increase of 62.56% from the latest price.
News
Pfizer has filed a lawsuit seeking to block Novo Nordisk from circumventing Pfizer's deal for weight-loss drug startup Metsera
The lawsuit says Novo Nordisk's offer for drug startup Metsera isn't reasonably likely to be completed.
Pfizer sues Metsera, Novo Nordisk over breach of merger deal
Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk , accusing them of breaking a merger agreement and interfering with the deal.
Novo Nordisk CEO says job cuts affecting 9,000 staff almost complete
Novo Nordisk has notified employees impacted by the drugmaker's job cuts in the vast majority of its locations although the pace varies according to local laws, its CEO Mike Doustdar wrote in a post o...
Two developments Thursday–Eli Lilly's strong quarterly performance and Novo Nordisk's unsolicited $9 billion bid for a startup–show why drugmakers can't get enough of weight loss
Lilly's quarterly results Thursday, combined with Novo Nordisk's unsolicited offer for a startup, confirm the $72 billion anti-obesity market is among pharma's hottest.
Novo Nordisk changes tack with bold raid on Pfizer obesity deal
Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the weight-loss drug market unde...
Metsera the US obesity biotech at centre of Novo, Pfizer bidding war
Metsera has become the obesity drug market's hottest ticket.
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).
Novo Nordisk says offer for Metsera adheres to restrictions under Pfizer deal
Novo Nordisk said on Thursday that it had adhered to all restrictions under the Pfizer merger agreement in its unsolicited offer for drugmaker Metsera , and that the value of its proposal far exceeded...
Invesco EQV International Equity Fund Q3 2025 Performance Update
Invesco EQV International Equity Fund's Q3 2025 performance was driven by strong returns from TSM, Legrand, Trip.com, and Shenzhen Inovance. TSM outperformed on robust AI chip demand and favorable mar...
Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker.
Denmark's Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.
Pfizer Addresses Proposal for Metsera
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a co...
Obesity drug rivalry heats up as Novo Nordisk tops Pfizer's bid for Metsera
In a move that highlights the escalating battle for dominance in the global weight-loss treatment market, Danish pharmaceutical giant Novo Nordisk A/S has made an improved takeover offer for US-based ...
Novo Nordisk Moves to Outbid Pfizer With Up to $9 Billion Offer for Obesity Drug Developer Metsera
Novo Nordisk said the proposal is currently subject to review by Metsera's board of directors.
Novo Nordisk makes unsolicited offer for Metsera
Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera.
Novo Nordisk submits proposal to acquire Metsera, Inc.
Bagsværd, Denmark, 30 October 2025 – Novo Nordisk confirms that it submitted an unsolicited proposal to acquire Metsera, Inc. (Metsera).
Novo Nordisk said to make higher bid for Metsera to challenge Pfizer, Bloomberg News reports
Danish drugmaker Novo Nordisk has made a higher offer for Metsera seeking to trump an agreed deal with Pfizer so it can consolidate its position in weight-loss medications, Bloomberg News reported on ...
Novo Nordisk: Decade-Low Valuation Meets A Billion-Patient Market
Initiating coverage on Novo Nordisk (NVO) with a Strong Buy 70% below its all-time high. NVO's competitive pressures and US political pricing risks are mid-term noise. Global obesity and diabetes mark...
Focus: Novo Nordisk's new chairman has 'carte blanche' after board clear-out
A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation, rattling investors despite calls for stronger leadership at the drugmaker behin...
Eli Lilly Accelerates On Obesity Data While Novo Nordisk Retreats
Eli Lilly is a Strong Buy, driven by exceptional growth in obesity and diabetes drugs Mounjaro and Zepbound, plus pipeline innovation. LLY's diversified business mix, global reach, and proactive U.S. ...
Novo Nordisk shares fall as top investor drives board overhaul
Shares in Novo Nordisk fell around 3% in early trading on Wednesday, extending their losses from a day earlier, after the Wegovy maker's top investor proposed a sweeping board overhaul.
Novo's board bust-up to sharpen drugmaker's focus on US consumers
Boardroom drama at Wegovy-maker Novo Nordisk has laid bare the company's biggest challenge: how to better tap into America's mass market for weight-loss drugs.
Healthy Returns: A key step forward for Novo Nordisk's GLP-1 pill
A closely watched pill from Novo Nordisk just scored an approval for slashing cardiovascular risks, while Mark Cuban gives Trump credit on drug prices.
Who's on Novo Nordisk's board after major shakeup?
Novo Nordisk will replace chair Helge Lund and six independent directors next month in a major boardroom shakeup following a disagreement over strategy with its powerful controlling shareholder, Novo ...
HSBC's Rajesh Kumar on Novo Nordisk: We want to see management team execute turnaround strategy
Rajesh Kumar, HSBC Sr. health care analyst, joins CNBC's 'Money Movers' to discuss his reaction to a board shakeup at Novo Nordisk.
Novo Nordisk's Entire Board Is Stepping Down. Here's Why.
The board turmoil represents a breakdown in relations between the company and its controlling shareholder.